BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Adherence of Apixaban and Warfarin in Patients With Arterial Fibrillation in Real-world Setting in Sweden

Completed

Conditions: Anticoagulation

First Posted Date: 2015-07-09

Last Posted Date: 2016-05-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 41000

Registration Number: NCT02492828

An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors

Phase 1

Completed

Conditions: Various Advanced Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: Daratumumab
Drug: Relatlimab

First Posted Date: 2015-07-02

Last Posted Date: 2023-11-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 578

Registration Number: NCT02488759

Locations: 🇺🇸
Local Institution - 0003, Atlanta, Georgia, United States
🇧🇪
Local Institution - 0012, Brussels, Belgium
🇺🇸
Local Institution - 0033, Tampa, Florida, United States

and more 37 locations

Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF2

Completed

Conditions: Non-valvular Atrial Fibrillation

First Posted Date: 2015-07-02

Last Posted Date: 2016-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 38122

Registration Number: NCT02488421

Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

Interventions: Drug: Amrubicin
Drug: Nivolumab
Drug: Topotecan

First Posted Date: 2015-06-25

Last Posted Date: 2023-07-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 569

Registration Number: NCT02481830

Locations: 🇺🇸
Local Institution - 0024, New Haven, Connecticut, United States
🇺🇸
Local Institution - 0173, Johnson City, New York, United States
🇧🇷
Local Institution - 0093, Barretos, Sao Paulo, Brazil

and more 148 locations

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Nivolumab
Drug: Carboplatin
Drug: Ipilimumab
Drug: Gemcitabine
Drug: Cisplatin
Drug: Pemetrexed
Drug: Paclitaxel

First Posted Date: 2015-06-23

Last Posted Date: 2024-11-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 2748

Registration Number: NCT02477826

Locations: 🇺🇸
Local Institution - 0017, San Francisco, California, United States
🇺🇸
Local Institution - 0115, Saint Louis, Missouri, United States
🇺🇸
Local Institution - 0014, Cleveland, Ohio, United States

and more 287 locations

Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen

Conditions: Squamous Non-Small Cell Lung Cancer
Non-squamous Non-Small Cell Lung Cancer

First Posted Date: 2015-06-18

Last Posted Date: 2020-11-27

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT02475382

Locations: 🇨🇦
Local Institution, Montreal, Quebec, Canada
🇨🇦
Centre De Sante Et De Services Sociaux Rimouski Neigette, Rimouski, Quebec, Canada

Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumor

Interventions: Drug: Ulocuplumab
Drug: Nivolumab

First Posted Date: 2015-06-16

Last Posted Date: 2018-11-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 61

Registration Number: NCT02472977

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
University Of Colorado Hosp, Aurora, Colorado, United States
🇺🇸
Columbia University Medical Center (Cumc), New York, New York, United States

and more 4 locations

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

Phase 4

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Apixaban
Drug: Standard of Care

First Posted Date: 2015-06-08

Last Posted Date: 2024-10-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 229

Registration Number: NCT02464969

Locations: 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States
🇺🇸
UF Health Shands Hospital, Gainesville, Florida, United States

and more 124 locations

Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy Patients

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Methotrexate, Leucovorin and BMS-986142
Drug: Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142

First Posted Date: 2015-05-29

Last Posted Date: 2016-02-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT02456844

Profile and Antithrombotic Management of Patients With NVAF Attending Internal Medicine Departments in Spain (PERFILAR Study)

Completed

Conditions: Anticoagulation, Blood Thinners , Atrial Fibrillation, Bleeding, Stroke

First Posted Date: 2015-05-18

Last Posted Date: 2017-05-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 987

Registration Number: NCT02447341

Locations: 🇪🇸
Local Institution, Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy